COMPARATIVE ANTIDIABETIC ACTIVITY OF MARKETED GLICLAZIDE FORMULATION WITH GLICLAZIDE LOADED PELLETS CONTAINING GUM KONDAGOGU AS A DRUG RETARDING MATERIAL IN RATS
Abstract
Controlled drug delivery systems significantly enhances therapeutic efficacy of drugs. Drug retarding polymers are the key performers in such designed systems.
Objective: The main objective of study is to evaluate antidiabetic effect of gliclazide loaded pellets developed by green synthesis technique where in gum Kondagogu is used as natural drug retarding polymer and compared with existing Gliclazide Marketed formulation.
 Methods: The study is carried out in Wistar rats with body weight ranging between 100-220g. Diabetes was induced in animals by injecting alloxan 150mg/kg/bodyweight intraperitoneally (i.p.). Animals were divided into four groups. Group I - Control, Group II- Diabetic Control, Group III- Diabetic treated with Gliclazide Marketed formulation, and Group IV- Diabetic treated with gliclazide loaded pellets orally. Fasting blood glucose levels were estimated at 0, 2, 4, 6, 8, 10, 12 and 24 hours to understand the release of the drug from polymer matrix.
Results: The results have shown that the on single oral administration of gliclazide loaded pellets coated with gum Kondagogu showed almost similar anti-diabetic activity when compared with marketed formulation The maximum reduction in the glucose level were observed at 4th and 6th hour and later the glucose levels were sustained in the same pattern to that of marketed formulation.
Conclusion: In the present study, an effort has been made to evaluate the efficacy of gum kondagogu as a novel controlled release matrix forming material and thus it could be concluded that gum kondagogu could be a controlled release matrix polymer and be a suitable substituent to existing synthetic polymers for drug retardation in the pharmaceutical industry.
Â
KEYWORDS: Gum Kondagogu, Gliclazide, tree gum exudates, natural drug retarding material
Downloads
References
Khan CR, Shechter. Oral hypoglycaemic agents and the pharmacology of the endocrine pancreas In: Theodore WR, Alan SN, Taylor P, Gilman Ag .eds. Goodman and Gilman’s.The pharmacology basis of therapeutic 8th edition New York: McGraw-Hill; 1991.
American Diabetes Association. Clinical Practice recommendation, Screening for diabetes, Diabetes care 1997; 20(1):22-24.
Campbell DB, Forette B, Rolland A, Hopkins YW, Gordon B, Williams JRB. Pharmacokinetics and Metabolism of gliclazide a review. Royal Soc. Med Int Congr Symp. 1980; 20: 71-82.
Sheskey PJ, Robb RT, Moore RD, Boyce BM. Effects of lubricant level, method of mixing and duration of mixing on a controlled release matrix tablet containing hydroxypropyl methyl cellulose. Drug dev. Industrial. Pharmacy.1995; 20:71-82.
Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix. AAPS Pharm Sci Tech. 2003; 4(3): E31.
Dale LM, Philip JC. Compressed Xanthan and Karaya gum matrices: hydration, erosion and drug release mechanisms. International journal of Pharmaceutics. 2000; 203:179-192.
Khullar P, Khar RK, Agarwal SP. Evaluation of guar gum in the preparation of sustained release matrix tablets. Drug. Dev. Industrial Pharmacy.1998; 24(11): 1095-1099.
Vinod VTP, Shashidar RB. Solution and conformational properties of gum kondagogu (Chlospermum gossypium)- A natural product with immune potential as a food additive. Food Chemistry. 2009; 116: 686-692.
Naidu VGM, Madhusudhan K, Shashidar RB, Ramakrishna S, Khar RK, Diwan PV. Polyelectrolyte complex of gum kondagogu and chitosan as diclofenac carriers. Carbohydr. Polym. 2009; 76: 464-471.
Murali MB, Himasankar K, Cheruvu CPN, Ramana Murthy KV. Controlled release of diclofenac sodium by Gum Karaya-Chitosan Complex Coacervate: In Vivo Evaluation. Indian J. Pharm. Sci. 2001; 63(5): 408-412.
Yashwant ND, Rajkapoor B. Design and evaluation of multiparticulate delivery system with different release profiles for the treatment of type II diabetes. J App Pharm. 2011; 03(03): 262-278.
Guidance for Industry. Estimating the maximum safe starting dose in intial clinical trials for therapeutic in adult healthy volunteers. US Department of Health and Human Resources, Food and Drug Administration, Centre for drug Evaluation and Research. July 2005:19.
Tenpe CR, Yoele PG. Comparative evaluation of antidiabetic activity of some marketed polyherbal formulations in alloxan induced diabetes rats. International J Pharm. Tesch. Resc, 2009;1(1) :43-49.
Ghosh S, Suryawanshi SA. Effect of vinca rosea extracts in the treatment of alloxan diabetes male albino rats. Ind. J. Exp. Biol, 2009; 39:748-789.
Stalin C, Dinesh kumar P, Nithaynanthan K. Evaluation of antidiabetic activity of methonolic leaf extract of Ficus Carica in Alloxan- induced Diabetic Rats. Asian Journal of Pharmaceutical and Clinical Research, 2012; 5(3): 85-87.
Molly SR, Dharsana JN, Soumya K, Vijayan N, Premkumar. Anti-diabetic activity of Anaphyllum wightii schott in alloxan induced diabetic rats. Asian Journal of Pharmaceutical and Clinical Research. 2013; 6(1): 68-69.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.